Quarterly ResultMay 15, 2026, 07:07 AM
Purple Biotech Q1 2026 Net Loss $0.089M; Cash $6.4M into 2027
AI Summary
Purple Biotech reported its first quarter 2026 financial results, with a net loss of $0.089 million, a decrease from $0.456 million in the prior year, primarily due to non-cash warrant-related income. The company maintained a cash position of $6.4 million as of March 31, 2026, expected to fund operations into 2027. Operationally, Purple Biotech highlighted new positive data for its lead candidate IM1240, established a Scientific Advisory Board for its CAPTN-3 platform, and expanded its AI collaboration with Converge Bio to accelerate antibody development.
Key Highlights
- Total cash position was $6.4 million as of March 31, 2026, providing runway into 2027.
- Net loss for Q1 2026 was $0.089 million, down from $0.456 million in Q1 2025.
- Research and Development expenses increased to $1.2 million in Q1 2026 from $0.8 million in Q1 2025.
- General and Administrative expenses rose to $1.0 million in Q1 2026 from $0.6 million in Q1 2025.
- Operating loss for Q1 2026 was $2.251 million, compared to $1.406 million in Q1 2025.
- New data for IM1240 tri-specific antibody showed potent anti-tumor activity across treatment-resistant patient-derived tumor samples.
- Established a CAPTN-3 Scientific Advisory Board with experts in T-cell engager development and oncology.
- Expanded collaboration with Converge Bio to apply generative AI for designing next-generation tri-specific antibodies.
Price Impact
More from PPBT